2269 — WuXi Biologics (Cayman) Share News
0.000.00%
Last trade - 00:00- HK$198.43bn
- HK$193.91bn
- CNY21.79bn
Hong Kong stocks climb, led by pharmaceutical, tech stocks
CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial
WuXi Biologics H1 net profit up on margin expansion
Brief: WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln
HK-listed WuXi XDC hits 10-month peak on solid first-half results
Chinese vaccine makers jump on news of key success in cancer treatment
Chinese vaccine makers jump on news of key success in cancer treatment, CanSino leads
WuXi Biologics hits 6-week high on confidence in delivering FY26 guidance
Brief: Wuxi Biologics Adds 69 Projects In Jan-April, Maintains Expected Revenue Growth
Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug
WuXi Biologics climbs most in six weeks on share repurchase plan
Brief: Wuxi Biologics To Repurchase Shares Up To Us$400 Million In Open Market
Brief: Wuxi Biologics Posts FY Revenue Of RMB21,790.0 Million
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares
WuXi Biologics climbs to 4-month high on robust earnings estimates
Brief: Wuxi Biologics FY Revenue RMB21,790 Million
Brief: Morgan Stanley’S Long Position In WuXi Biologics (Cayman) Decreases To 2.11% On Jan 20 From 5.58%, HKEX Shows
Brief: Wuxi Biologics (Cayman) Says Wuxi Biologics Holdings Enters Block Trade Agreement With Morgan Stanley
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares